Serum immunoglobulin levels in group E of chronic obstructive pulmonary disease: insights for clinical management and immunoglobulin therapy strategies

• Published in: BMC pulmonary medicine Vol. 24; no. 1; pp. 381 - 10
• Main Authors: Hai, Cong Nguyen, Ba, Thang Ta, Duc, Thanh Bui, Xuan, Cuong Hoang, Manh, Tan Vu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.08.2024; BioMed Central; BMC
• Subjects: Aged; Blood; Bronchitis; Care and treatment; Case-Control Studies; Chronic illnesses; Chronic obstructive pulmonary disease; Clinical outcomes; Common variable immunodeficiency; COPD; CVID; Disease Progression; Female; Health aspects; Humans; Immune system; Immunoglobulin A; Immunoglobulin A - blood; Immunoglobulin defficiency; Immunoglobulin E; Immunoglobulin G; Immunoglobulin G - blood; Immunoglobulin M; Immunoglobulin M - blood; Immunoglobulin therapy; Immunoglobulins; Immunoglobulins - blood; Immunotherapy; Infections; IVIG; Leukocytes; Lung diseases; Lung diseases, Obstructive; Male; Medical research; Medicine, Experimental; Methods; Middle Aged; Patients; Physiological aspects; Prospective Studies; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - immunology; Pulmonary Disease, Chronic Obstructive - therapy; Tuberculosis; Variables; Vietnam; CVID; IVIG; Immunoglobulin defficiency; Immunoglobulin therapy; COPD
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-024-03185-5

The study aimed to characterize serum immunoglobulin (Ig) concentrations and their relationship with clinical and paraclinical features in patients with COPD group E in the stable stage. Additionally, the study focused on evaluating the relationship between serum Ig levels and the risk of exacerbations over the next 12 months, thereby clarifying the role of serum Ig deficiency in affecting the future risk for these patients. A prospective observational study assessed IgG, IgA, IgM, and IgE levels in 67 COPD patients and 30 healthy controls at Military Hospital 103 from October 2017 to August 2020. Primary outcomes included Ig isotype levels in COPD patients, with secondary outcomes exploring differences compared to controls and associations with clinical variables. COPD patients showed significantly lower IgG concentrations and higher IgA levels than controls. IgM and IgE levels did not differ significantly. Subgroup analysis revealed notable decreases in IgG1 and IgG3 concentrations, with 10.4% of patients exhibiting reduced IgG levels and 0.3% diagnosed with common variable immunodeficiency. No significant associations were found between Ig levels and exacerbation risk or clinical variables. Serum IgG and IgM concentrations were significantly reduced in COPD patients compared to normal individuals, with IgG1 and IgG3 concentrations notably low. Serum IgA levels were significantly higher in COPD patients compared with normal controls. However, no significant association was found between Ig concentrations, particularly serum IgG deficiency and its subclasses, with the frequency and risk of exacerbations during 12 months of longitudinal follow-up. Caution is warranted in the use of immunoglobulin therapy in the treatment of COPD patients. An independent ethics committee approved the study (Ethics Committee of Military Hospital 103 (No. 57/2014/VMMU-IRB), which was performed in accordance with the Declaration of Helsinki, Guidelines for Good Clinical Practice.